RAD
RADIOPHARM THERANOSTICS LIMITEDRadiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
RAD
RAD
RADIOPHARM THERANOSTICS LIMITED
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Fundamentals
Historical Data52 days
| Date | Short % | Gross Short |
|---|---|---|
| 15 Sept | 1.24% | — |
| 1 Sept | — | — |
| 31 Aug | — | — |
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | — | — |
| 24 Aug | — | — |
| 21 Aug | — | — |
| 20 Aug | — | — |
| 19 Aug | — | — |
| 18 Aug | — | — |
Radiopharm Theranostics Limited (RAD) Short Interest Summary
Radiopharm Theranostics Limited (RAD) currently has 1.24% of its shares sold short (53.8 million shares, worth approximately $538K), based on ASIC short position data reported on 15 September 2026 (T+4 reporting lag). That makes RAD the #228 most shorted stock on the ASX most shorted list. Short interest in RAD is up 1.22% over the past week and up 1.21% over the past month. RAD is part of the Health Care sector on the ASX.
Recent RAD Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 15 Sept 2026 | 1.24% | 53.8M | — |
| 3 Aug 2026 | 0.02% | 0.9M | $0.01 |
| 31 July 2026 | 0.26% | 10.0M | $0.01 |
| 30 July 2026 | 0.26% | 10.0M | $0.01 |
| 29 July 2026 | 0.02% | 0.9M | $0.01 |
| 28 July 2026 | 0.02% | 0.9M | $0.01 |
| 27 July 2026 | 0.02% | 0.9M | $0.01 |
| 24 July 2026 | 0.02% | 0.9M | $0.02 |
| 23 July 2026 | 0.02% | 0.9M | $0.02 |
| 22 July 2026 | 0.02% | 0.9M | $0.02 |
RAD Short Selling — Frequently Asked Questions
What is Radiopharm Theranostics Limited (RAD)'s current short interest?
Radiopharm Theranostics Limited (RAD) currently has a short interest of 1.24% of total shares outstanding. This means 1.24% of RAD's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is RAD heavily shorted on the ASX?
RAD has a relatively low short interest of 1.24%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for RAD investors?
Short interest in RAD shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 1.24%, RAD's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this RAD short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for RAD.